iTeos Therapeutics’ (ITOS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a report published on Friday,Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.

Separately, Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research note on Thursday.

iTeos Therapeutics Trading Down 3.4 %

Shares of NASDAQ ITOS opened at $7.68 on Friday. The firm has a fifty day simple moving average of $8.74 and a two-hundred day simple moving average of $12.92. The firm has a market capitalization of $280.58 million, a PE ratio of -2.44 and a beta of 1.37. iTeos Therapeutics has a 12 month low of $7.44 and a 12 month high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. On average, sell-side analysts predict that iTeos Therapeutics will post -3.46 earnings per share for the current year.

Insider Activity at iTeos Therapeutics

In related news, CFO Matthew Gall purchased 5,000 shares of iTeos Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the purchase, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This represents a 8.27 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Candriam S.C.A. purchased a new position in iTeos Therapeutics during the second quarter valued at approximately $7,558,000. State Street Corp boosted its holdings in shares of iTeos Therapeutics by 21.9% in the 3rd quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after buying an additional 211,452 shares in the last quarter. Clearline Capital LP bought a new position in shares of iTeos Therapeutics during the 2nd quarter worth approximately $2,328,000. Algert Global LLC lifted its position in iTeos Therapeutics by 92.0% during the third quarter. Algert Global LLC now owns 256,139 shares of the company’s stock valued at $2,615,000 after acquiring an additional 122,730 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after acquiring an additional 117,159 shares in the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.